Know Labs, INC 8-K filings

Know Labs, Inc. has announced a registered direct offering of units, each consisting of one share of common stock and one warrant, with expected gross proceeds of approximately $300,000.

Know Labs has been granted an extension until March 27, 2026, by the NYSE American to regain compliance with listing standards.

Know Labs Inc. stockholders approved an increase in authorized shares and amendments to the 2021 Equity Incentive Plan at a special meeting on October 25, 2024.

Know Labs has amended its senior secured convertible notes, extending the maturity date by one year and increasing the interest rate from 6% to 8%.

Know Labs has amended its original 8-K filing to correct an item reference, with no changes to the original disclosure regarding the results of its 2024 Annual Meeting of Stockholders.

Know Labs has received a notice from the NYSE American for not meeting minimum stockholders' equity requirements and must submit a plan to regain compliance by October 27, 2024.

Know Labs held its 2024 Annual Meeting of Stockholders on September 26, 2024, where shareholders elected directors, ratified the accounting firm, and approved the issuance of shares related to convertible notes and warrants.

Know Labs announces the resignation of director Timothy Londergan and the appointment of Ichiro Takesako to the Audit Committee.

Know Labs, Inc. has successfully completed a registered direct offering, raising $1.655 million through the sale of units consisting of common stock and warrants.

Know Labs, Inc. successfully closed a $3.445 million public offering to fund the development of its non-invasive glucose monitoring technology.

Know Labs' study published in Diabetes Technology & Therapeutics demonstrates 93.37% accuracy in classifying glycemic status using a non-invasive radiofrequency sensor.

Know Labs has entered into an agreement to sell up to $5 million of its common stock through an at-the-market offering.

Know Labs has entered into a securities purchase agreement with Lind Global Fund II, LP, securing up to $12 million through a convertible note offering, with an initial $4 million tranche already funded.

Know Labs announced interim results from a clinical study showing its non-invasive glucose monitor achieved an 11.1% Mean Absolute Relative Difference (MARD) using venous blood as a reference.

Know Labs has entered into a funding agreement with Lind Global Fund II LP for up to $12 million to accelerate its clinical research and development initiatives.

Know Labs has announced the KnowU, a wearable non-invasive continuous glucose monitor, incorporating a sensor intended for FDA submission.

Know Labs reported a reduced net loss for the first quarter of fiscal year 2024 and is planning to raise additional capital through equity and debt offerings.